Femasys Inc., a company listed on NASDAQ under the ticker FEMY, has released a corporate presentation focused on its advancements in women's reproductive health. The presentation highlights the company's main areas of focus, including infertility, contraception, and cancer diagnostics, with products such as FemaSeed® Intratubal Insemination, FemVue® Contrast-Generating Device, FemBloc® Permanent Birth Control, and FemCerv® Endocervical Tissue Sampler. As of June 30, 2025, Femasys reported a stock price of $0.97 and a market capitalization of $31.4 million. The company emphasizes its commercialization efforts for the infertility portfolio, initiated in late 2024, and holds an intellectual property portfolio with approximately 200 global patents. Femasys also notes its global regulatory approvals across several regions, including the U.S., Europe, and Japan. You can access the full presentation through the link below.